{"id":2334,"date":"2015-09-18T15:49:29","date_gmt":"2015-09-18T15:49:29","guid":{"rendered":"https:\/\/medicalcriteria.com\/web\/hethl\/"},"modified":"2026-03-18T19:35:09","modified_gmt":"2026-03-18T19:35:09","slug":"hethl","status":"publish","type":"post","link":"https:\/\/medicalcriteria.com\/web\/hethl\/","title":{"rendered":"WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues"},"content":{"rendered":"<div class=\"99c380e4b4a7b96c35d7ddf7dcb434e8\" data-index=\"1\" style=\"float: none; margin:0px 0 0px 0; text-align:center;\">\n<script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js\"><\/script>\r\n<!-- MC 2019- Horizontal -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-0127150553352455\"\r\n     data-ad-slot=\"3806776041\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script>\n<\/div>\n<p>The World Health Organization classification of lymphoid neoplasms updated in 2008 represents a worldwide consensus on the diagnosis of these tumors and is based on the recognition of distinct diseases, using a multidisciplinary approach.<br \/>\n<!--more--><br \/>\n<b>WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues<\/b><br \/>\n<b>Mature B-cell neoplasms<\/b><\/p>\n<ul>\n<li>Chronic lymphocytic leukemia\/small lymphocytic lymphoma<\/li>\n<li>B-cell prolymphocytic leukemia<\/li>\n<li>Splenic marginal zone lymphoma<\/li>\n<li>Hairy cell leukemia<\/li>\n<li>Splenic lymphoma\/leukemia, unclassifiable*<\/li>\n<\/ul>\n<p>-Splenic diffuse red pulp small B-cell lymphoma*<br \/>\n-Hairy cell leukemia variant*<\/p>\n<ul>\n<li>Lymphoplasmacytic lymphoma<\/li>\n<\/ul>\n<p>-Waldenstr\u00f6m macroglobulinemia<\/p>\n<ul>\n<li>Heavy chain diseases<\/li>\n<\/ul>\n<p>-Alpha Heavy chain disease<br \/>\n-Gamma Heavy chain disease<br \/>\n-Mu Heavy chain disease<\/p>\n<ul>\n<li>Plasma cell myeloma<\/li>\n<li>Solitary plasmacytoma of bone<\/li>\n<li>Extraosseous plasmacytoma<\/li>\n<li>Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)<\/li>\n<li>Nodal marginal zone lymphoma<\/li>\n<\/ul>\n<p>-Pediatric nodal marginal zone lymphoma*<\/p>\n<ul>\n<li>Follicular lymphoma<\/li>\n<\/ul>\n<p>-Pediatric follicular lymphoma*<\/p>\n<ul>\n<li>Primary cutaneous follicle centre lymphoma<\/li>\n<li>Mantle cell lymphoma<\/li>\n<li>Diffuse large B-cell lymphoma (DLBCL), NOS<\/li>\n<\/ul>\n<p>-T-cell\/histiocyte rich large B-cell lymphoma<br \/>\n-Primary DLBCL of the CNS<br \/>\n-Primary cutaneous DLBCL, leg type<br \/>\n-Epstein\u2013Barr virus (EBV)-positive DLBCL of the elderly*<\/p>\n<ul>\n<li>DLBCL associated with chronic inflammation<\/li>\n<li>Lymphomatoid granulomatosis<\/li>\n<li>Primary mediastinal (thymic) large B-cell lymphoma<\/li>\n<li>Intravascular large B-cell lymphoma<\/li>\n<li>ALK-positive large B-cell lymphoma<\/li>\n<li>Plasmablastic lymphoma<\/li>\n<li>Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease<\/li>\n<li>Primary effusion lymphoma<\/li>\n<li>Burkitt lymphoma<\/li>\n<li>B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma<\/li>\n<li>B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma<\/li>\n<\/ul>\n<p><b>Mature T-cell and NK-cell neoplasms<\/b><\/p>\n<ul>\n<li>T-cell prolymphocytic leukemia<\/li>\n<li>T-cell large granular lymphocytic leukemia<\/li>\n<li>Chronic lymphoproliferative disorder of NK cells*<\/li>\n<li>Aggressive NK-cell leukemia<\/li>\n<li>Systemic EBV-positive T-cell lymphoproliferative disease of childhood<\/li>\n<li>Hydroa vacciniforme-like lymphoma<\/li>\n<li>Adult T-cell leukemia\/lymphoma<\/li>\n<li>Extranodal NK\/T-cell lymphoma, nasal type<\/li>\n<li>Enteropathy-associated T-cell lymphoma<\/li>\n<li>Hepatosplenic T-cell lymphoma<\/li>\n<li>Subcutaneous panniculitis-like T-cell lymphoma<\/li>\n<li>Mycosis fungoides<\/li>\n<li>S\u00e9zary syndrome<\/li>\n<li>Primary cutaneous CD30+ T-cell lymphoproliferative disorders<\/li>\n<\/ul>\n<p>-Lymphomatoid papulosis<br \/>\n-Primary cutaneous anaplastic large cell lymphoma<\/p>\n<ul>\n<li>Primary cutaneous gamma-delta T-cell lymphoma<\/li>\n<li>Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma*<\/li>\n<li>Primary cutaneous CD4+ small\/medium T-cell lymphoma*<\/li>\n<li>Peripheral T-cell lymphoma, NOS<\/li>\n<li>Angioimmunoblastic T-cell lymphoma<\/li>\n<li>Anaplastic large cell lymphoma, ALK-positive<\/li>\n<li>Anaplastic large cell lymphoma, ALK-negative*<\/li>\n<\/ul>\n<p><b>Hodgkin lymphoma<\/b><\/p>\n<ul>\n<li>Nodular lymphocyte predominant Hodgkin lymphoma<\/li>\n<li>Classical Hodgkin lymphoma<\/li>\n<li>Nodular sclerosis classical Hodgkin lymphoma<\/li>\n<li>Lymphocyte-rich classical Hodgkin lymphoma<\/li>\n<li>Mixed cellularity classical Hodgkin lymphoma<\/li>\n<li>Lymphocyte-depleted classical Hodgkin lymphoma<\/li>\n<\/ul>\n<p><b>Histiocytic and dendritic cell neoplasms<\/b><\/p>\n<ul>\n<li>Histiocytic sarcoma<\/li>\n<li>Langerhans cell histiocytosis<\/li>\n<li>Langerhans cell sarcoma<\/li>\n<li>Interdigitating dendritic cell sarcoma<\/li>\n<li>Follicular dendritic cell sarcoma<\/li>\n<li>Fibroblastic reticular cell tumor<\/li>\n<li>Intermediate dendritic cell tumor<\/li>\n<li>Disseminated juvenile xanthogranuloma<\/li>\n<\/ul>\n<p><b>Posttransplantation lymphoproliferative disorders (PTLDs)<\/b><\/p>\n<ul>\n<li>Early lesions<\/li>\n<\/ul>\n<p>-Plasmacytic hyperplasia<br \/>\n-Infectious mononucleosis\u2013like PTLD<\/p>\n<ul>\n<li>Polymorphic PTLD<\/li>\n<li>Monomorphic PTLD (B- and T\/NK-cell types)\u2020<\/li>\n<li>Classical Hodgkin lymphoma type PTLD\u2020<\/li>\n<\/ul>\n<p>NOS indicates not otherwise specified; ALK, anaplastic lymphoma kinase; HHV8, human herpesvirus 8; and NK, natural killer.<br \/>\n*These histologic types are provisional entities for which the WHO Working Group felt there was insufficient evidence to recognize as distinct diseases at this time.<br \/>\n\u2020These lesions are classified according to the leukemia or lymphoma to which they correspond.<\/p>\n<p>&nbsp;<\/p>\n<p><b>References:<\/b><\/p>\n<ol>\n<li>Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications.\u00a0Blood. 2011 May 12;117(19):5019-32.\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/21300984\/\" target=\"_blank\" rel=\"noopener noreferrer\">[Medline]<\/a><\/li>\n<li>Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstr\u00f6m-Lindberg E, Tefferi A, Bloomfield CD. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.\u00a0Blood. 2009 Jul 30;114(5):937-51.\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/19357394\/\" target=\"_blank\" rel=\"noopener noreferrer\">[Medline]<\/a><\/li>\n<li>Thiele J, Kvasnicka HM, Orazi A, Gianelli U, Gangat N, Vannucchi AM, Barbui T, Arber DA, Tefferi A. The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms. Am J Hematol. 2023 Jan;98(1):166-179. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36200127\/\" target=\"_blank\" rel=\"noopener\">[Medline]<\/a><\/li>\n<\/ol>\n<p>&nbsp;<\/p>\n<p>Created Nov 12, 2015.<br \/>\nUp-date Mar 18, 2026.<\/p>\n\n<div style=\"font-size: 0px; height: 0px; line-height: 0px; margin: 0; padding: 0; clear: both;\"><\/div>","protected":false},"excerpt":{"rendered":"<p>Sorry, this entry is only available in Espa\u00f1ol.<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"no","_lmt_disable":"no","_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[171],"tags":[166,167,751,750,749,748,747,746,745,744,306],"class_list":["post-2334","post","type-post","status-publish","format-standard","hentry","category-hematology","tag-clasificacion","tag-classification","tag-hematopoietic","tag-hematopoyeticos","tag-linfoides","tag-lymphoid","tag-tejidos","tag-tissues","tag-tumores","tag-tumors","tag-who"],"modified_by":"Guillermo Firman","_links":{"self":[{"href":"https:\/\/medicalcriteria.com\/web\/wp-json\/wp\/v2\/posts\/2334","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicalcriteria.com\/web\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicalcriteria.com\/web\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicalcriteria.com\/web\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/medicalcriteria.com\/web\/wp-json\/wp\/v2\/comments?post=2334"}],"version-history":[{"count":4,"href":"https:\/\/medicalcriteria.com\/web\/wp-json\/wp\/v2\/posts\/2334\/revisions"}],"predecessor-version":[{"id":10718,"href":"https:\/\/medicalcriteria.com\/web\/wp-json\/wp\/v2\/posts\/2334\/revisions\/10718"}],"wp:attachment":[{"href":"https:\/\/medicalcriteria.com\/web\/wp-json\/wp\/v2\/media?parent=2334"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicalcriteria.com\/web\/wp-json\/wp\/v2\/categories?post=2334"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicalcriteria.com\/web\/wp-json\/wp\/v2\/tags?post=2334"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}